Pharmacotherapy for the management of obesity

Metabolism: Clinical and Experimental

Volumn 64, Issue 11, 2015, Pages 1376-1385

  Patel, Dhiren ^a,b  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

Obesity; Obesity management; Pharmacotherapy; Weight loss

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; AMFEPRAMONE; ANTIOBESITY AGENT; BENZPHETAMINE; BETA CAROTENE; DEXFENFLURAMINE; FENFLURAMINE; LIRAGLUTIDE; LORCASERIN; MULTIVITAMIN; PHENDIMETRAZINE; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PHENTERMINE RESIN; PLACEBO; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ABDOMINAL PAIN; BACKACHE; BARIATRIC SURGERY; BEHAVIOR CHANGE; BODY WEIGHT MANAGEMENT; CARDIOMETABOLIC RISK; CLINICAL TRIAL (TOPIC); COMORBIDITY; CONSTIPATION; COUGHING; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSGEUSIA; DYSPEPSIA; EPIDEMIC; FATIGUE; FECES INCONTINENCE; FLATULENCE; GASTRIC BANDING; HEALTH CARE PERSONNEL; HUMAN; HYPOGLYCEMIA; INSOMNIA; LIFESTYLE MODIFICATION; LONG TERM CARE; META ANALYSIS; METABOLIC PARAMETERS; NAUSEA; OBESITY; PARESTHESIA; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SLEEVE GASTRECTOMY; SPOTTING; TREATMENT DURATION; TREATMENT INDICATION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ANTI-OBESITY AGENTS; HUMANS; OBESITY;

EID: 84944441506     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2015.08.001     Document Type: Review

References (58)

1. Z.Y. Zhang, and M.W. Wang Obesity, a health burden of a global nature Acta Pharmacol Sin 33 2012 145 147
2. C.L. Ogden, M.D. Carroll, B.K. Kit, and K.M. Flegal Prevalence of childhood and adult obesity in the United States, 2011-2012 JAMA 311 2014 806 814
3. WHO Obesity and overweight. WHO fact sheet N°311 World Health Organization website 2015 World Health Organization Geneva, Switzerland [http://www.who.int/mediacentre/factsheets/fs311/en. Accessed July 22, 2015]
4. M. Ng, T. Fleming, M. Robinson, B. Thomson, N. Graetz, C. Margono, and et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013 Lancet 384 2014 766 781
5. M.D. Jensen, D.H. Ryan, C.M. Apovian, J.D. Ard, A.G. Comuzzie, K.A. Donato, and et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society J Am Coll Cardiol 63 2014 2985 3023
6. B. Shrager, G.A. Jibara, P. Tabrizian, S. Roayaie, and S.C. Ward Resection of nonalcoholic steatohepatitis-associated hepatocellular carcinoma: a Western experience Int J Surg Oncol 2012 2012 915128
7. E.E. Calle, C. Rodriguez, K. Walker-Thurmond, and M.J. Thun Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults N Engl J Med 348 2003 1625 1638
8. American Medical Association AMA adopts new policies on second day of voting at annual meeting 2013 American Medical Association Chicago, IL [http://www.ama-assn.org/ama/pub/news/news/2013/2013-06-18-new-ama-policies-annual-meeting.page. Accessed July 22, 2015]
9. B.K. Kit, C.L. Ogden, and K.M. Flegal Prescription medication use among normal weight, overweight, and obese adults, United States, 2005-2008 Ann Epidemiol 22 2012 112 119
10. Y.C. Wang, K. McPherson, T. Marsh, S.L. Gortmaker, and M. Brown Health and economic burden of the projected obesity trends in the USA and the UK Lancet 378 2011 815 825
11. D. Withrow, and D.A. Alter The economic burden of obesity worldwide: a systematic review of the direct costs of obesity Obes Rev 12 2011 131 141
12. K. Fujioka Benefits of moderate weight loss in patients with type 2 diabetes Diabetes Obes Metab 12 2010 186 194
13. R.F. Kushner, and D.H. Ryan Assessment and lifestyle management of patients with obesity: clinical recommendations from systematic reviews JAMA 312 2014 943 952
14. R.R. Henry, R. Chilton, and W.T. Garvey New options for the treatment of obesity and type 2 diabetes mellitus (narrative review) J Diabetes Complications 27 2013 508 518
15. J.C. Seger, D.B. Horn, E.C. Westman, R. Lindquist, W. Scinta, L.A. Richardson, and et al. Obesity Algorithm®. American Society of Bariatric Physicians website http://www.asbp.org/obesityalgorithm.html [Accessed July 22, 2015]
16. C.M. Apovian, L.J. Aronne, D.H. Bessesen, M.E. McDonnell, M.H. Murad, U. Pagotto, and et al. Pharmacological management of obesity: an Endocrine Society Clinical Practice Guideline J Clin Endocrinol Metab 100 2015 342 362
17. T.A. Wadden, S. Volger, A.G. Tsai, D.B. Sarwer, R.I. Berkowitz, L.K. Diewald, and et al. Managing obesity in primary care practice: an overview and perspective from the POWER-UP study Int J Obes (Lond) 37 Suppl. 1 2013 S3 S11
18. FDA approves first-of-kind device to treat obesity Food and Drug Administration website 2015 [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm430223.htm. Accessed July 22, 2015]
19. S.Z. Yanovski, and J.A. Yanovski Long-term drug treatment for obesity: a systematic and clinical review JAMA 311 2014 74 86
20. J.G. Kang, and C.Y. Park Anti-obesity drugs: a review about their effects and safety Diabetes Metab J 36 2012 13 25
21. W.P. James, I.D. Caterson, W. Coutinho, N. Finer, L.F. Van Gaal, A.P. Maggioni, and et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects N Engl J Med 363 2010 905 917
22. G.W. Kim, J.E. Lin, E.S. Blomain, and S.A. Waldman New advances in models and strategies for developing anti-obesity drugs Expert Opin Drug Discov 8 2013 655 671
23. G. Cosentino, A.O. Conrad, and G.I. Uwaifo Phentermine and topiramate for the management of obesity: a review Drug Des Devel Ther 7 2013 267 278
24. XENICAL (orlistat) capsules for oral use Prescribing Information 2013 Genentech USA, Inc. South San Francisco, CA
25. J.S. Torgerson, J. Hauptman, M.N. Boldrin, and L. Sjostrom XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients Diabetes Care 27 2004 155 161
26. BELVIQ (lorcaserin hydrochloride) US Prescribing Information 2014 Eisai Inc. Woodcliff Lake, NJ
27. S.R. Smith, N.J. Weissman, C.M. Anderson, M. Sanchez, E. Chuang, S. Stubbe, and et al. Multicenter, placebo-controlled trial of lorcaserin for weight management N Engl J Med 363 2010 245 256
28. M.C. Fidler, M. Sanchez, B. Raether, N.J. Weissman, S.R. Smith, W.R. Shanahan, and et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial J Clin Endocrinol Metab 96 2011 3067 3077
29. P.M. O'Neil, S.R. Smith, N.J. Weissman, M.C. Fidler, M. Sanchez, J. Zhang, and et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study Obesity (Silver Spring) 20 2012 1426 1436
30. QSYMIA (phentermine and topiramate extended-release) Capsules Prescribing Information 2014 VIVUS, Inc. Mountain View, CA
31. K.M. Gadde, D.B. Allison, D.H. Ryan, C.A. Peterson, B. Troupin, M.L. Schwiers, and et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial Lancet 377 2011 1341 1352
32. D.B. Allison, K.M. Gadde, W.T. Garvey, C.A. Peterson, M.L. Schwiers, T. Najarian, and et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP) Obesity (Silver Spring) 20 2012 330 342
33. W.T. Garvey, D.H. Ryan, M. Look, K.M. Gadde, D.B. Allison, C.A. Peterson, and et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study Am J Clin Nutr 95 2012 297 308
34. F.L. Greenway, K. Fujioka, R.A. Plodkowski, S. Mudaliar, M. Guttadauria, J. Erickson, and et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Lancet 376 2010 595 605
35. CONTRAVE (naltrexone HCl and bupropion HCl) extended-release tablets Prescribing Information 2014 Takeda Pharmaceuticals America, Inc. Deerfield, IL
36. C.M. Apovian, L. Aronne, D. Rubino, C. Still, H. Wyatt, C. Burns, and et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II) Obesity (Silver Spring) 21 2013 935 943
37. T.A. Wadden, J.P. Foreyt, G.D. Foster, J.O. Hill, S. Klein, P.M. O'Neil, and et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial Obesity (Silver Spring) 19 2011 110 120
38. P. Hollander, A.K. Gupta, R. Plodkowski, F. Greenway, H. Bays, C. Burns, and et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes Diabetes Care 36 2013 4022 4029
39. SAXENDA (liraglutide [rDNA origin] injection) Prescribing Information 2014 Novo Nordisk Inc. Plainsboro, NJ
40. T.A. Wadden, P. Hollander, S. Klein, K. Niswender, V. Woo, P.M. Hale, and et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study Int J Obes (Lond) 37 2013 1443 1451
41. G.A. Bray, and D.H. Ryan Update on obesity pharmacotherapy Ann N Y Acad Sci 1311 2014 1 13
42. L. van Bloemendaal, J.S. Ten Kulve, S.E. la Fleur, R.G. Ijzerman, and M. Diamant Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS J Endocrinol 221 2014 T1 T16
43. F.L. Greenway, M.J. Whitehouse, M. Guttadauria, J.W. Anderson, R.L. Atkinson, K. Fujioka, and et al. Rational design of a combination medication for the treatment of obesity Obesity (Silver Spring) 17 2009 30 39
44. Alli (orlistat) Product Label 2014 GlaxoSmithKline Consumer Healthcare Moon Township, PA
45. D. Rucker, R. Padwal, S.K. Li, C. Curioni, and D.C. Lau Long term pharmacotherapy for obesity and overweight: updated meta-analysis BMJ 335 2007 1194 1199
46. L.K. Heisler, E.E. Jobst, G.M. Sutton, L. Zhou, E. Borok, Z. Thornton-Jones, and et al. Serotonin reciprocally regulates melanocortin neurons to modulate food intake Neuron 51 2006 239 249
47. W.J. Thomsen, A.J. Grottick, F. Menzaghi, H. Reyes-Saldana, S. Espitia, D. Yuskin, and et al. Lorcaserin, a novel selective human 5-hydroxytryptamine(2C) agonist: in vitro and in vivo pharmacological characterization J Pharmacol Exp Ther 325 2008 577 587
48. 2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis Neuron 60 2008 582 589
49. E.D. Berglund, C. Liu, J.W. Sohn, T. Liu, M.H. Kim, C.E. Lee, and et al. Serotonin 2C receptors in pro-opiomelanocortin neurons regulate energy and glucose homeostasis J Clin Invest 123 2013 5061 5070
50. N.J. Weissman, M. Sanchez, G.G. Koch, S.R. Smith, W.R. Shanahan, and C.M. Anderson Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials Circ Cardiovasc Imaging 6 2013 560 567
51. Qsymia Risk Evaluation and Mitigation Strategy (REMS) Qsymia website 2015 VIVUS Inc Mountain View, CA [http://www.qsymiarems.com/index.html. Accessed July 22, 2015]
52. J. Jordan, A. Astrup, S. Engeli, K. Narkiewicz, W.W. Day, and N. Finer Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity J Hypertens 32 2014 1178 1188
53. N. Katsiki, A.I. Hatzitolios, and D.P. Mikhailidis Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'? Ann Med 43 2011 249 258
54. VICTOZA (liraglitude injection) Prescribing Information 2013 Novo Nordisk Inc. Plainsboro, NJ
55. FDA approves weight-management drug Saxenda Food and Drug Administration website 2014 [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427913.htm. Accessed July 22, 2015]
56. Saxenda Risk Evaluation and Mitigation Strategy (REMS) 2014 Novo Nordisk Inc Plainsboro, NJ [http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM428537.pdf. Accessed July 22, 2015]
57. Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE™ - Diabetes 2014 [Clinicaltrials.gov website. Accessed July 22, 2015]
58. X. Pi-Sunyer, A. Astrup, K. Fujioka, F. Greenway, A. Halpern, M. Krempf, and et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management N Engl J Med 373 2015 11 22